Clinical uses of intravenous immunoglobulin.
作者信息
Jolles S, Sewell W A C, Misbah S A
机构信息
Department of Clinical Immunology, Royal Free Hospital London, UK.
出版信息
Clin Exp Immunol. 2005 Oct;142(1):1-11. doi: 10.1111/j.1365-2249.2005.02834.x.
Abstract
摘要
相似文献
1
Clinical uses of intravenous immunoglobulin.
Clin Exp Immunol. 2005 Oct;142(1):1-11. doi: 10.1111/j.1365-2249.2005.02834.x.
2
Supply, use, and abuse of intravenous immunoglobulin.
Curr Opin Pediatr. 1999 Dec;11(6):533-9. doi: 10.1097/00008480-199912000-00011.
3
Intravenous immunoglobulin in autoimmune and inflammatory diseases: more than mere transfer of antibodies.
Transfus Apher Sci. 2007 Aug;37(1):103-7. doi: 10.1016/j.transci.2007.01.012. Epub 2007 Aug 31.
4
[Intravenous immunoglobulins in dermatology].
Ann Dermatol Venereol. 2002 Aug-Sep;129(8-9):1078-81.
5
The role of intravenous immunoglobulins in pediatric diseases.
Indian Pediatr. 1999 Jan;36(1):51-63.
6
7th International Immunoglobulin Conference: Mechanisms of action.
Clin Exp Immunol. 2014 Dec;178 Suppl 1(Suppl 1):87-8. doi: 10.1111/cei.12523.
7
Immune supplementation and immune modulation with intravenous immunoglobulin.
J Allergy Clin Immunol. 2005 Oct;116(4):941-4. doi: 10.1016/j.jaci.2005.07.021.
8
Immunoglobulins and their use in children.
Adv Clin Exp Med. 2015 Jan-Feb;24(1):153-9. doi: 10.17219/acem/28626.
9
Intravenous immune globulin use in children. Infectious Diseases and Immunization Committee, Canadian Paediatric Society.
CMAJ. 1992 Jan 15;146(2):121-4.
10
[Functional mechanisms of intravenous immunoglobulins].
Acta Clin Belg. 1998 Dec;53(6):360-6. doi: 10.1080/17843286.1998.11754192.
引用本文的文献
1
Sepsis: the evolution of molecular pathogenesis concepts and clinical management.
MedComm (2020). 2025 Feb 23;6(3):e70109. doi: 10.1002/mco2.70109. eCollection 2025 Mar.
2
Autoantibodies in COVID-19: implications for disease severity and clinical outcomes.
Front Immunol. 2025 Jan 6;15:1509289. doi: 10.3389/fimmu.2024.1509289. eCollection 2024.
3
Induced B-Cell Receptor Diversity Predicts PD-1 Blockade Immunotherapy Response.
bioRxiv. 2024 Dec 4:2024.12.03.626669. doi: 10.1101/2024.12.03.626669.
4
The Emerging Role of Immunoglobulins and Complement in the Stimulation of Neuronal Activity and Repair: Not as Simple as We Thought.
Biomolecules. 2024 Oct 18;14(10):1323. doi: 10.3390/biom14101323.
5
Cardiac injury progression in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection: a review.
Front Pediatr. 2024 Mar 6;12:1348016. doi: 10.3389/fped.2024.1348016. eCollection 2024.
6
The use of intravenous immunoglobulin in intensive care.
BJA Educ. 2024 Jan;24(1):31-37. doi: 10.1016/j.bjae.2023.10.004. Epub 2023 Nov 27.
7
Mechanism underlying polyvalent IgG-induced regulatory T cell activation and its clinical application: Anti-idiotypic regulatory T cell theory for immune tolerance.
Front Immunol. 2023 Nov 29;14:1242860. doi: 10.3389/fimmu.2023.1242860. eCollection 2023.
8
Comparative effectiveness of two intravenous immunoglobulin products in children with Kawasaki disease, a nationwide cohort study.
Sci Rep. 2023 Oct 30;13(1):18629. doi: 10.1038/s41598-023-45092-5.
9
Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection.
Cochrane Database Syst Rev. 2023 Oct 23;10(10):CD009417. doi: 10.1002/14651858.CD009417.pub3.
10
Case report: Clinical experience of treating pembrolizumab-induced systemic capillary leak syndrome (SCLS) in one patient with metastatic gastroesophageal junction squamous cell carcinoma.
Pathol Oncol Res. 2023 Sep 8;29:1611330. doi: 10.3389/pore.2023.1611330. eCollection 2023.
本文引用的文献
1
Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases.
Ann Rheum Dis. 2005 Jun;64(6):913-20. doi: 10.1136/ard.2004.029694. Epub 2004 Nov 18.
2
Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial.
Lancet. 2004;364(9440):1149-56. doi: 10.1016/S0140-6736(04)17101-8.
3
Natural antibodies sustain differentiation and maturation of human dendritic cells.
Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14210-5. doi: 10.1073/pnas.0402183101. Epub 2004 Sep 20.
4
Treatment of autoimmune mucocutaneous blistering diseases with intravenous immunoglobulin therapy.
Expert Opin Investig Drugs. 2004 Aug;13(8):1019-32. doi: 10.1517/13543784.13.8.1019.
5
A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies.
Clin Immunol. 2004 Jun;111(3):303-10. doi: 10.1016/j.clim.2003.11.002.
6
Successful treatment of scleromyxoedema with high dose intravenous immunoglobulin.
Clin Exp Dermatol. 2004 May;29(3):317-8. doi: 10.1111/j.1365-2230.2004.01518.x.
7
Increased risk of adverse events when changing intravenous immunoglobulin preparations.
Clin Exp Immunol. 2004 Apr;136(1):111-3. doi: 10.1111/j.1365-2249.2004.02412.x.
8
Efficacy of intravenous immunoglobulin on the prevention of pneumonia in patients with agammaglobulinemia.
FEMS Immunol Med Microbiol. 2004 Mar 8;40(2):113-8. doi: 10.1016/S0928-8244(03)00304-3.
9
Intravenous immunoglobulin and autoimmune thrombocytopenic purpura: 22 years on.
Vox Sang. 2004 Jan;86(1):8-14. doi: 10.1111/j.0042-9007.2004.00391.x.
10
Intravenous immunoglobulin for Guillain-Barré syndrome.
Cochrane Database Syst Rev. 2004(1):CD002063. doi: 10.1002/14651858.CD002063.pub2.
Zotero 插件